Norisuke Nakayama

Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial

Kohei Shitara, Atsuo Takashima, Kazumasa Fujitani et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 215 citations

Gastrointestinal Oncology, Medicine, Advanced Gastric Cancer +5

Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial

Yasuhide Yamada, Narikazu Boku, Junki Mizusawa et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 121 citations

S-1 Versus Cisplatin, Gastrointestinal Oncology, Advanced Gastric Cancer +8

Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)

Katsuhiko Higuchi, Satoshi Tanabe, Ken Shimada et al. · European Journal of Cancer · 2014 · 81 citations

Second-line Treatment, Gastrointestinal Oncology, Advanced Gastric Cancer +9

A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)

Wasaburo Koizumi, Norisuke Nakayama, Satoshi Tanabe et al. · Cancer Chemotherapy and Pharmacology · 2011 · 74 citations

Surgical Oncology, Gastrointestinal Oncology, Recurrent Gastric Cancer +8

S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial

Yoon‐Koo Kang, Keisho Chìn, Hyun Cheol Chung et al. · The Lancet Oncology · 2020 · 73 citations · Full text

First-line Therapy, Oncology, Gastrointestinal Oncology +9